Novartis makes final Zolgensma pitch before FDA decision

Pre-symptomatic patients with the most severe form of spinal muscular atrophy showed sustained improvement following intravenous treatment with Novartis' experimental gene therapy Zolgensma, according to a data presentation at the American Academy of Neurology.